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Background: Microcytosis, smaller than normal red blood cells, has previously been identified as a 
possible early risk marker for some cancers. The role of microcytosis across all cancers has not been 
fully investigated. 
 
Aim: To examine cancer incidence in a cohort of patients with microcytosis, with or without 
accompanying anaemia  
 
Design and setting: Cohort study of patients aged ≥40 years using UK primary care electronic patient 
records.  
 
Methods: The 1-year cancer incidence was compared between cohorts of patients with a mean red 
cell volume of < 85fL (low) or 85fL-101fL (normal). Further analyses examined gender, age-group and 
cancer site, and haemoglobin values.  
 
Results: 497 out of 12,289 patients with microcytosis had a new cancer diagnosis within 1 year 
(4.0%, 95% confidence interval 3.7 to 4.4), compared to 1,465 of 73,150 without microcytosis (2.0%, 
CI 1.9 to 2.1). In males, 298 out of 4,800 with microcytosis developed cancer (6.2%, CI 5.5 to 6.9), 
compared to 940 out of 34,653 without (2.7%, CI 2.5 to 2.9). In females with microcytosis, 199 out of 
7,489 developed cancer (2.7%, CI 2.3 to 3.1), compared to 525 out of 38,497 without (1.4%, CI 1.3 to 
1.5). In patients with microcytosis but normal haemoglobin, 86 out of 2,637 males (3.3%, CI 2.6 to 
4.0) and 101 out of 5,055 females (2.0%, CI 1.6 to 2.4) were diagnosed with cancer. 
 
Conclusions:  
Microcytosis is a predictor of underlying cancer even if haemoglobin is normal. Although a benign 
explanation is more likely, clinicians in primary care should consider simple testing for cancer in 
unexplained microcytosis, particularly in males. 
 





How this fits in 
Microcytosis has long been recognised with iron deficiency and with haemoglobinopathies. Similarly, 
iron deficiency has been identified as a feature of some cancers, particularly colorectal. However, 
the relationship between microcytosis and other cancers was largely unknown, including the 
importance of microcytosis without anaemia. This study has found an overall cancer risk in those 
aged 40years of 6.2% in males and 2.7% in females, with colorectal and lung cancer the most 
frequent. Further, even with a normal haemoglobin, microcytosis represents a small – but real – risk 
of underlying cancer. 
  
Introduction 
There were 163,444 deaths from cancer in the UK in 2016,(1) accounting for more than a quarter 
(28%) of all UK deaths.(2) Whilst cancer survival rates are improving, the UK still lags behind many 
other economically developed countries internationally(3, 4) and has generally lower survival rates 
than comparable European countries.(5) These differences are due in part to delays in diagnosis,(3) 
with cancers in the UK diagnosed at a later stage compared to other European countries.(6) The NHS 
long term plan, released in 2019, targets that by 2028 the proportion of cancers diagnosed at stages 
1 and 2 will rise from around half now to three quarters.(7) It is important for primary care clinicians 
to recognise features of possible cancer in order to investigate appropriately.(8) 
Some previous primary care research studies have found a number of blood test features to be 
associated with cancer that could act as early risk markers. These include: thrombocytosis,(9) raised 
inflammatory markers,(10)  hypoalbuminaemia(11) and hypercalcaemia.(12) Thrombocytosis was 
more commonly associated with patients who had lung and colorectal cancers, and one third of the 
patients with lung or colorectal cancer and thrombocytosis had no other symptoms indicating 
malignancy.(9) A study into early detection of multiple myeloma in primary care found an 
association between myeloma and macrocytosis. (13) 
Previous studies have recently identified microcytosis (smaller than normal red blood cells) as a 
potential early risk marker for certain cancers including: lymphoma,(14) oesophago-gastric,(15) 
colorectal,(16) and kidney cancer.(17) These risks were independent of any anaemia. The precise 
role of microcytosis in primary care across all cancers is not currently known, particularly in patients 






This cohort study used electronic patient records from the Clinical Practice Research Datalink (CPRD) 
which holds anonymised primary care records from a network of over 1,400 UK practices. It includes 
information on symptoms, referrals and laboratory tests.(18) The cases for this study were derived 
from the control sample of previously published CPRD studies.(12,19) CRPD cases were patients 
aged ≥40 years with a record of cancer at 1 of 13 cancer sites between 2000 and 2009. Each case 
was matched to five controls with no record of the cancer of interest at the diagnosis date of the 
case, but could have any other cancer. Matching was done by sex, practice and year of birth. (12, 19) 
 
Patient sample 
108,993 patients were studied with a mean cell volume (MCV) result between 2006 and 2008 and 
who were aged ≥40 years at the time of testing. We chose 2006 as a starting point to account for the 
introduction of the Quality and Outcomes Framework, and the NICE Guideline, Referral for 
Suspected Cancer in 2005,(20) and a cut off of 2008 allowed for one year follow up for looking at 
cancer diagnoses. Patients were grouped into either: microcytosis or a normal MCV. An upper 
boundary for microcytosis was chosen as 85 femtolitres (fL) due to the common use of that value as 
a threshold in UK practice, though 80fL is commonly used in North America.(21) Patients with MCV 
values below 50fl were excluded, for two reasons: the result could have been erroneous, and even if 
not, clinically such patients are likely to warrant investigation on such an extreme finding alone. The 
index date was defined as the date of the first MCV result. A comparison sub-cohort of patients with 
a normal MCV, defined as 85-101fL, were used with the same age and date criteria. Values above 
101fL were defined as macrocytosis and were therefore excluded. Haemoglobin values reported on 
the same day as the MCV were also identified. We excluded patients diagnosed with cancer (other 
than non-melanoma skin cancer) before the index date from both study and comparison groups. 
 
Cancer outcomes 
New diagnoses of cancer (other than non-melanoma skin cancer) within 1 year of the index date 
were found by searching the patient records, using a previously published list of cancer codes 
(available from authors on request).  
 
Statistical methods and analysis 
The primary analysis was the 1-year cancer incidence, expressed as a percentage (with 95% 
confidence intervals) for patients in the microcytosis group and for the normal MCV group. This one-
year incidence could be regarded as a positive predictive value for microcytosis. 
Further sub-analyses were performed by sex, age-group and cancer site. Additional analyses 
examined the incidence in patients with a second MCV test result within 3 months and 6 months of 
the index test; the incidence in the microcytosis group if the upper threshold were lowered to 80fL, 
and the period between test date and cancer diagnosis. Cancer incidences in patients with 
microcytosis with or without anaemia are also reported. Anaemia was defined as below 13.0g/dl for 




After all exclusions, there were 85,439 participants: 12,289 with microcytosis and 73,150 with a 
normal MCV. (Figure1) In the microcytosis cohort, the median age was 73 years (interquartile range= 
64 to 81); 4,800 were male (39.1%). In the normal cohort there were 73,150 patients, with a median 
age of 71 (63 to 79) and 34,653 being male (47.4%).  
 
    Figure 1 here 
 
Cancer diagnoses 
497 patients in the microcytosis group had a cancer diagnosis, representing a 1-year cancer 
incidence of 4.0% (CI 3.7 to 4.4). In the normal group 1,465 patients were diagnosed with cancer, a 
1-year cancer incidence of 2.0% (CI 1.9 to 2.1). The median age at cancer diagnosis in the 
microcytosis group was 76 years (interquartile range= 70 to 83) and for the normal group it was 75 
(68 to 81).  
 
Gender 
The 1-year cancer incidence was higher in males for both groups with 298 of 4,800 males with 
microcytosis (6.2%, CI 5.5 to 6.9), and 199 of 7,489 females (2.7%, 2.3 to 3.1). In males with a normal 
MCV 940 of 34,653 were diagnosed with cancer (2.7%, 2.5 to 2.9), and 525 of 38,497 females (1.4%, 
1.3 to 1.5). (Table 1). The cancer incidence with microcytosis was higher than with a normal MCV 
across both age groups, the highest cancer incidence being in males over 70 with microcytosis, with 
225 out of 3,008 developing cancer (7.5%, 6.6 to 8.5).  
 
   Table 1 here 
 
Cancer sites 
The cancer sites for the two genders are shown in Figure 2. Cancer sites that made up a greater 
proportion of cancers diagnosed in the microcytosis cohort than the normal cohort were: colorectal 
(113, 23%), lung (67, 13%), lymphoma (24, 5%), kidney (22, 4%) and stomach (15, 3%).  
 
Figure 2 here 
 
In the microcytosis cohort, 3,187 participants had a second MCV result within 3 months of the index 
date (74.6% of these also showed microcytosis). In those who remained microcytic 175 out of 2,377 
were diagnosed with cancer (7.4%, CI 6.3 to 8.5) compared to 27 of 809 (3.3%, CI 2.2 to 4.8) in those 
whose second MCV was within the normal range. Similar figures were found for repeat blood test 
within six months.  
Reanalysis using 80fL as the upper limit for the microcytosis group increased the cancer incidence in 
those with an ‘abnormal’ result to 190 out of 2940 overall (6.5%, 5.6 to 7.4), with 120 of 1,101 males 
(10.9%, 9.1 to 12.9) and 70 of 1,839 females (3.8%, 3.0 to 4.8). In the microcytosis group, the median 
period between the index date and cancer diagnosis was 80 days, whereas in the normal MCV group 
the median period to cancer diagnosis was 113 days. 
  
Concomitant anaemia 
2,162 of 4,799 (45%) males and 2,433 of 7,488 (32%) females in the microcytosis group also had 
anaemia at the index date. Two cases apparently had a second blood test on the index date yielding 
a discordant result. These two were omitted from this sub-analysis. In those with microcytosis and 
anaemia, 212 of 2,162 males (9.8%, CI 8.6 to 11.1) and 98 of 2,433 females (4.0%, 3.3 to 4.9) were 
diagnosed with cancer. In those with microcytosis and normal haemoglobin, 86 of 2,637 males 
(3.3%, 2.6 to 4.0) and 101 of 5,055 females (2.0%, 1.6 to 2.4) were diagnosed with cancer within a 
year. Colorectal cancer was the most common cancer in all females and males with microcytosis and 
anaemia, whereas in males with microcytosis only, prostate was the most common. (Table 2) 
 
   Table 2 here  
Discussion 
Summary 
This study is the first to report the incidence of cancer in patients with microcytosis compared to 
those with a normal MCV in primary care across all cancer types. The overall 1-year cancer incidence 
in those with microcytosis was 4.0%, (3.7 to 4.4), compared to 2.0% (1.9 to 2.1) in those with a 
normal MCV. The difference was more marked in males, with 6.2% (5.5 to 6.9) of microcytic patients 
developing cancer, and only 2.7% (2.3 to 3.1) of females doing so.  Individual cancers that were 
disproportionately more common with microcytosis were colorectal, lung, lymphoma, kidney and 
stomach. In patients who had microcytosis but with normal haemoglobin, 3.3% (2.6 to 4.0) of men 
and 2.0% (1.6 to 2.4) of women had a diagnosis of cancer within a year. 
 
Strengths and limitations 
The large size of this study is a key strength, as well as the setting in primary care - where patients 
often present symptoms that could trigger cancer investigation. The study is largely representative 
of the UK population, other than the matching to a previous cancer case population. This may have 
increased the cancer risk in the population, but should have done so equally for those with 
microcytosis and their comparison group.  The study is reliant on the quality of CRPD data: however 
since 2000, laboratory test data has been automatically transmitted to most GP practices (16) which 
considerably reduces the chance of transcription error. We do not know why the blood test was 
taken. Blood tests are commonly performed in primary care for many different reasons: around 1 in 
4 of the adult UK population have a full blood count in any one year.(16) Even so, the quarter of the 
over 40s population who have had a blood test and so are expected to be a somewhat more ill 
population. This is why the comparison cohort used were patients with a ‘normal’ MCV result rather 
than the untested population. We used an upper threshold of 85fL to define ‘microcytosis’ - a 
conservative choice, though reflecting common UK practice. 
 
Comparison with existing literature 
The results of this study largely agree with previous CPRD studies that found that microcytosis was 
associated with: non-Hodgkin lymphoma,(14) oesophago-gastric cancer(15) and kidney cancer.(17) 
The association between microcytosis and colorectal cancer reported from another case-control 
study (16) also supports our findings. No primary care study has reported cancer incidence with 
microcytosis across all cancers, or in patients with normal haemoglobin. Secondary care studies of 
microcytosis concentrate on iron-deficiency anaemia and possible causes of the anaemia, and we 
could find no reports on microcytosis unaccompanied by anaemia.  
 
Implications for research and practice 
 Although the risk of cancer with microcytosis is above the 3% figure that NICE recommend for 
urgent cancer investigation, general practitioners have in house tests to help in this situation. This 
increased risk is made up of a small number of cancers - particularly colorectal - as shown in figures 
2a and 2b. There seems to be no effect for some other cancers, for example, breast. For general 
practitioners, an MCV is only reported alongside the haemoglobin value. Anaemia accompanied by 
microcytosis strongly suggests iron-deficiency, and so measurement of iron stores (which were too 
few in our study for reliable analysis) would be the usual next step. If iron deficiency is identified, its 
cause will be sought, which would generally involve examining for gastro-intestinal blood loss. This 
diagnostic pathway does not remove the need to enquire about other symptoms suggestive of one 
of the malignancies we report here, particularly lung cancer. What this study changes however, is for 
patients with microcytosis but without anaemia. Some may be iron-deficient, simplifying the 
investigation strategy. It seems sensible for all these patients also to be offered faecal 
immunochemical testing for hidden gastrointestinal blood loss, plus a chest X-ray if respiratory 
symptoms suggest lung cancer is possible. In such a way, the small number of patients whose 
microcytosis has been caused by cancer could receive a more timely diagnosis, whilst not exposing 
the majority to unnecessary referral and invasive testing. 
 
Conclusion 
Patients in primary care with microcytosis may harbour cancer, with colorectal and lung cancers the 
most probable. Most of the relevant initial investigations are available in primary care allowing initial 
assessment of possible cancer to be performed rapidly.  
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Figure 1. Exclusions flow diagram showing the number of patients excluded for having an MCV less 
than 50, MCV over 101, non-melanoma skin cancer, microcytosis in the 12 months before index 
date, or pre-existing cancer, and the number included in the microcytosis and normal MCV cohorts. 
  
 Microcytosis Normal MCV 














Males 4,800 298 6.21% (5.54 
to 6.93) * 
34,653 940 2.71% (2.54 
to 2.89) 
Females 7,489 199 2.66% (2.30 
to 3.05) 
38,497 525 1.36% (1.25 
to 1.48) 
Aged 40-69 4,647 125 2.69% (2.24 
to 3.20) 
32,631 437 1.34% (1.22 
to 1.47) 
Aged 70+ 7,642 372 4.87% (4.40 
to 5.37) * 
40,519 1,028 2.54% (2.39 
to 2.69) 
 
* Incidence above 3% NICE threshold for referral 
Table 1. The number of patients in the cohort, the number with cancer and the cancer incidence for 




 Male Female 
 Microcytosis and 




anaemia n=2,433 (%) 
Microcytosis only 
n=5,055 (%) 
 No cancer 1,950 
(90%) 
No cancer 2,551 
(97%) 
No cancer 2,335  
(96%) 
No cancer 4,954 
 (98%) 
1 Colorectal, 56 (2.6%)  Prostate, 27 (1.0%) Colorectal, 34 (1.4%) Colorectal, 14 (0.3%) 
2 Prostate, 28 (1.3%)  Lung, 15 (0.6%) Breast, 10 (0.4%) Lung, 14 (0.3%) 
3 Lung, 28 (1.3%) Colorectal, 9 (0.3%) Lung 10 (0.4%) Breast, 13 (0.3%) 
 
Table 2. The 3 most common cancer sites in males and females both with microcytosis and anaemia, 
and with microcytosis only, the number and percentage of the group without cancer, and the 
number and percentage with cancer at each site. 
  
 
Figure 2a. The most commonly diagnosed cancer types in females with microcytosis compared to 
the general UK female population. The inner ring shows the proportions of the most common cancer 
types in the microcytosis cohort. The outer ring shows the proportions of incidences of these types 
in the general population in 2015. 
Figure 2b. The most commonly diagnosed cancer types in males with microcytosis compared to the 
general UK male population. The inner ring shows the proportions of the most common cancer types 
in the microcytosis cohort. The outer ring shows the proportions of incidences of these types in the 
general population in 2015. 
